Are nilotinib-associated vascular adverse events an under-estimated problem?
Author:
Affiliation:
1. Department of Pharmacology; Regional Pharmacovigilance Center; Nice France
2. Haematology Department; Centre Hospitalo-Universitaire; Nice France
3. Haematology Department; Centre Antoine-Lacassagne; Nice France
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/fcp.12102/fullpdf
Reference21 articles.
1. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N. Engl. J. Med.,2010
2. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study;Giles;Expert Rev. Hematol.,2010
3. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results;Kantarjian;Blood,2011
4. First-line therapy for chronic myeloid leukemia: new horizons and an update;Saglio;Clin. Lymphoma Myeloma Leuk.,2010
5. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia;Stein;BMC Cancer,2013
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Drug-induced cardiac toxicity and adverse drug reactions, a narrative review;Therapies;2023-10
2. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies;Seminars in Cancer Biology;2022-11
3. Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia;JMV-Journal de Médecine Vasculaire;2021-04
4. Severe hypertensive flare‐up after intravitreal injection of ranibizumab for retinal venous branch occlusion;Fundamental & Clinical Pharmacology;2020-12-10
5. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib;International Journal of Cardiology;2020-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3